share_log

Individual Investors Invested in Sino Medical Sciences Technology Inc. (SHSE:688108) up 17% Last Week, Insiders Too Were Rewarded

Individual Investors Invested in Sino Medical Sciences Technology Inc. (SHSE:688108) up 17% Last Week, Insiders Too Were Rewarded

个人投资者上周投资了新医科技股份有限公司(SHSE:688108)的股票,涨幅达17%,内部人士也得到了回报
Simply Wall St ·  2024/08/31 08:22

Key Insights

主要见解

  • Significant control over Sino Medical Sciences Technology by individual investors implies that the general public has more power to influence management and governance-related decisions
  • 51% of the business is held by the top 14 shareholders
  • 27% of Sino Medical Sciences Technology is held by insiders
  • 个人投资者对华科医疗科技具有重要控制权,这意味着普通公众更有力量影响管理和治理决策。
  • 14位最大股东持有该业务的51%。
  • 27%的华科医疗科技股权由内部人持有。

To get a sense of who is truly in control of Sino Medical Sciences Technology Inc. (SHSE:688108), it is important to understand the ownership structure of the business. With 42% stake, individual investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

要了解谁真正控制着华科医疗科技公司(SHSE:688108),重要的是了解该公司的所有权结构。个人投资者持有公司42%的股份,拥有最大的股份。也就是说,该集团是最有可能在股票上涨时受益(或在股票下跌时损失最惨)。

While individual investors were the group that benefitted the most from last week's CN¥513m market cap gain, insiders too had a 27% share in those profits.

尽管个人投资者在上周的人民币51300万市值增长中受益最多,但内部人员也分享了27%的利润。

In the chart below, we zoom in on the different ownership groups of Sino Medical Sciences Technology.

在下面的图表中,我们将重点关注中医药科技的不同所有权群体。

1725063741287
SHSE:688108 Ownership Breakdown August 31st 2024
SHSE:688108所有权分布2024年8月31日

What Does The Institutional Ownership Tell Us About Sino Medical Sciences Technology?

机构所有权告诉我们有关中医药科技的什么?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。

Sino Medical Sciences Technology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Sino Medical Sciences Technology's historic earnings and revenue below, but keep in mind there's always more to the story.

中医药科技已经在股份登记册上拥有机构。事实上,他们在公司拥有可观的持股。这可能表明公司在投资界拥有一定的信誉度。然而,最好仍然谨慎依赖于机构投资者所谓的认可。他们有时也会犯错。当多个机构持有一支股票时,总会存在它们参与'拥挤交易'的风险。当这种交易出错时,多个方可能会竞相快速卖出股票。这种风险在一个没有增长历史的公司中更高。您可以在下面看到中医药科技的历史收益和营业收入,但请记住故事总是更多。

1725063743051
SHSE:688108 Earnings and Revenue Growth August 31st 2024
SHSE:688108股票的盈利和营业收入增长情况于2024年8月31日公布。

We note that hedge funds don't have a meaningful investment in Sino Medical Sciences Technology. With a 20% stake, CEO Jianhua Sun is the largest shareholder. Guotai Asset Management Company Limited is the second largest shareholder owning 6.8% of common stock, and Yanchao Guo holds about 5.5% of the company stock.

我们注意到对冲基金对中国医学科技公司的投资并不重要。首席执行官孙建华持有20%的股份,是最大的股东。国泰资产管理有限公司是第二大股东,持有公司普通股的6.8%,而郭延超持有公司约5.5%的股份。

After doing some more digging, we found that the top 14 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.

经过进一步的调查,我们发现前14名股东持有该公司的51%的股份,这表明没有单一的股东对该公司拥有重要的控制权。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

研究机构所有权是衡量和筛选股票预期表现的好方法。研究分析师的看法也可以达到同样的效果。股票的分析师覆盖率很低,但不多。因此,可以有更多的空间来增加其覆盖范围。

Insider Ownership Of Sino Medical Sciences Technology

中国医学科技公司内部持股情况

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

虽然内部人员的具体定义可能是主观的,但几乎所有人都认为董事会成员是内部人员。公司管理层应向董事会回答问题,后者应代表股东的利益。值得注意的是,有时高层管理人员也会成为董事会成员。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部人士持股是一件好事。但是,在某些情况下,它会使其他股东更难以对董事会的决定进行问责。

Our most recent data indicates that insiders own a reasonable proportion of Sino Medical Sciences Technology Inc.. Insiders have a CN¥971m stake in this CN¥3.5b business. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

我们最近的数据表明,内部人员拥有中国医药科技股份有限公司的一定比例。内部人员在这家市值35亿的公司中拥有约97100万人民币的股份。我们认为这显示了与股东的契合度,但值得注意的是,该公司仍然相当小。一些内部人员可能是公司的创始人。您可以点击这里查看这些内部人员的买入和卖出情况。

General Public Ownership

一般大众所有权

The general public-- including retail investors -- own 42% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

普通公众,包括零售投资者,拥有42%的股份,因此不能被轻易忽视。虽然这样的持股规模可能不足以在其利益方面左右政策决策,但他们仍然可以对公司政策产生集体影响。

Private Company Ownership

私有公司的所有权

We can see that Private Companies own 8.2%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我们可以看到,私人公司拥有已发行股份的8.2%。但仅从这一事实本身很难得出任何结论,因此有必要研究拥有这些私人公司的人员。有时,内部人员或其他相关方可能通过独立的私人公司持有公共公司的股份。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Sino Medical Sciences Technology better, we need to consider many other factors.

总是值得考虑持有一家公司股份的不同群体。但要更好地了解中华医学科技,我们需要考虑许多其他因素。

I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.

我总是喜欢查看营业收入增长的历史记录,你也可以免费访问这个详细图表中的历史营收和收益图表。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

最终,未来最重要。您可以在这份关于该公司分析师预测的免费报告中获取有关信息。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发